[1] MONTGOMERY EA. Oesophageal cancer//World Cancer Report 2014[M]. Stewart BW,Wild CP. Lyon:International Agency for Research on Cancer,2014:374-382.[2] 姜琳娜,路三军,桂红武,等. Slug、E-cadherin、Vimentin 及MMP-9在食管鳞状细胞癌侵袭转移中的作用[J]. 现代中西医结合杂志,2015,24(6):586-589.[3] ZHANG W,FENG M,ZHANG G,et al. Chemoresistance to 5-fluorouracil induces esithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells[J]. Biochem Biophys Res Commun,2012,417(2):679-685.[4] 朱晓燕,刘鲁明,陈震,等. 华蟾素联合健择对人胰腺癌PANC-1细胞增殖及细胞周期的影响[J]. 上海中医药杂志,2013,47(4):85-88.[5] 付海燕,高山,田莉莉,等. 华蟾素注射液对与人淋巴管内皮细胞共培养下人肝癌HepG2 细胞的增殖及侵袭的影响[J]. 中国临床药理学杂志,2013,29(3):199-201.[6] 张建. 华蟾素注射液联合化疗治疗中晚期肺癌69例疗效观察[J]. 中国医药指南,2013,11(24):285-286.[7] 牛凯,成宇晶. 华蟾素对人肝癌细胞Bel-7402细胞增殖及周期的影响[J]. 山西中医,2013,29(3):47-49.[8] 李丹丹. 华蟾素注射液联合顺铂治疗非小细胞肺癌患者的临床疗效及对免疫功能的影响[J]. 临床医药实践,2015,24 (5):332-334.[9] 陈彬. 华蟾素联合GP方案治疗中晚期非小细胞肺癌的临床疗效和抗肿瘤机理[J]. 实用癌症杂志,2016,31(2):224-227.[10] 朱晨宇,王广胜,杨振华,等. 华蟾素对直肠癌SW480 细胞生长影响的实验研究[J]. 现代肿瘤医学,2016,4 (15):2356-2359.[11] 乔翠霞,张新峰,蔡小平,等. 华蟾素抑制人胃癌BGC-823细胞体外侵袭、迁移的机理[J]. 中成药,2015,37(8):1655-1659.[12] ROOMI M W,MONTERREY J C,KALINOVSKY T,et al. Inhibition of invasion and MMPs by a nutrient mixture in human cancer cell lines:a correlation study[J]. Exp Oncol,2010,32(4):243-248.[13] BAE M J. Prognostic role of MMPs in colorectal cancer[J]. J Korean Soc Coloproctol,2011,27(3):105-103.[14] OHSAWA M,IKURA Y,FUKUSHIMA H,et al. Immuno-histochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma[J]. Oncology,2005,68(4/5/6):422-431.[15] LU D,SHI H C,WANG Z X,et al. Multidrug resistance associated biomarkers PGP,GST-pi,Topo-II and LRP as prognostic factors in primary ovarian carcinoma[J]. Br J Biomed Sci,2011,2:69-74.[16] 袁凯,付荣湛,孙勇. P-糖蛋白和肺耐药蛋白在浸润性乳腺癌中的表达及其临床意义[J]. 中华乳腺病杂志(电子版),2010,4(4):410-416.[17] TSAI J H,YANG J. Epithelial mesenchymal plasticity in carcinoma metastasis[J]. Genes Dev,2013,27(20):2192-2206.[18] 郭苏阳,李胜泽,郭伟,等. Twist和E-cadherin在宫颈鳞癌中的表达及其与KAI1表达的关系[J]. 华中科技大学学报(医学版),2015,44(4):411-415.[19] GLOUSHANKOVA N A. Changes in regulation of cell-cell adhesion during tumor transformation[J]. Biochemistry,2008,73(7):742-750.[20] 蔡晓曼,陈素钻,俞晶,等. 小窝蛋白-1和E-钙黏蛋白在食管癌TE1细胞系中的表达及其意义[J]. 癌变·畸变·突变,2016,28(3):227-230.[21] GEIGER T,SABANAY H,KRAVCHENKO-BALASHA N,et al. Anomalous features of EMT during keratinocyte transformation[J]. PLoS One,2008,3(2):1574.[22] 唐勇,王辉,陈伟娟,等. EMT经p38-MAPK调节乳腺癌MCF-7细胞P-gp介导的多药耐药[J]. 中国肿瘤生物治疗杂志,2010,17(1):144-148.[23] CREIGHTON C J,LI X,LANDIS M,et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features[J]. Proc Natl Acad Sci USA,2009,106(33):13820-13825.[24] SAXENA M,STEPHENS M A,PATHAK H,et al. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC Transporters[J]. Cell Death Dis,2011,2:179.[25] 张自森,李灿宇,王宁,等. RNA干涉E-cadherin表达对乳腺癌细胞紫杉醇化疗敏感性的影响[J]. 中国妇幼保健,2014,29 (7):1106-1108. |